Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.890,50
1,59%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Verastem Inc (VSTM) Verastem Inc (VSTM) Notizie

VSTM

Verastem (VSTM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VSTM
DataOraFonteTitoloSimboloCompagnia
18/04/202422:05Business WireVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical OfficerNASDAQ:VSTMVerastem Inc
04/04/202413:30Business WireVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VSTMVerastem Inc
18/03/202412:00Business WireGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
14/03/202421:05Business WireVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business UpdatesNASDAQ:VSTMVerastem Inc
11/03/202422:07Edgar (US Regulatory)Form SC TO-I/A - Tender offer statement by Issuer: [Amend]NASDAQ:VSTMVerastem Inc
11/03/202412:30Business WireVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet NeedsNASDAQ:VSTMVerastem Inc
05/03/202423:27Business WireVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
05/03/202422:30Business WireVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024NASDAQ:VSTMVerastem Inc
08/02/202422:22Edgar (US Regulatory)Form SC TO-I - Tender offer statement by IssuerNASDAQ:VSTMVerastem Inc
02/02/202415:49Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:VSTMVerastem Inc
29/01/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VSTMVerastem Inc
29/01/202413:00Business WireVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven CancersNASDAQ:VSTMVerastem Inc
18/01/202422:00Business WireVerastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)NASDAQ:VSTMVerastem Inc
11/01/202413:00Business WireVerastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:VSTMVerastem Inc
09/01/202422:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VSTMVerastem Inc
19/12/202322:01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:VSTMVerastem Inc
18/12/202313:00Business WireVerastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet TherapeuticsNASDAQ:VSTMVerastem Inc
13/12/202313:00Business WireVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
08/12/202322:10Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:VSTMVerastem Inc
21/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VSTMVerastem Inc
13/11/202313:00Business WireNew Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment ApproachNASDAQ:VSTMVerastem Inc
08/11/202323:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VSTMVerastem Inc
08/11/202322:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VSTMVerastem Inc
08/11/202322:12Business WireVerastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:VSTMVerastem Inc
07/11/202313:00Business WireFirst-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian CancerNASDAQ:VSTMVerastem Inc
06/11/202313:00Business WireVerastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient PopulationNASDAQ:VSTMVerastem Inc
26/10/202322:05Business WireVerastem Oncology Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:VSTMVerastem Inc
14/10/202318:30Business WireVerastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung CancerNASDAQ:VSTMVerastem Inc
28/09/202320:15Business WireVerastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development SummitNASDAQ:VSTMVerastem Inc
05/09/202313:00Business WireVerastem Oncology to Participate in Upcoming Investor ConferencesNASDAQ:VSTMVerastem Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VSTM

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network